News
科思
/
/
/
Evaluation of the Biodegradable Peripheral Igaki-Tamai Stent in the Treatment

Evaluation of the Biodegradable Peripheral Igaki-Tamai Stent in the Treatment

  • Categories:Academic Paper
  • Author:
  • Origin:
  • Time of issue:2016-08-12 09:22
  • Views:

(Summary description)This study sought to evaluate the safety and performance of the Igaki-Tamai (Igaki Medical Planning Company, Kyoto, Janpan) biodegradable stent in patients with occlusive superficial femoral artery (SFA) disease.

Evaluation of the Biodegradable Peripheral Igaki-Tamai Stent in the Treatment

(Summary description)This study sought to evaluate the safety and performance of the Igaki-Tamai (Igaki Medical Planning Company, Kyoto, Janpan) biodegradable stent in patients with occlusive superficial femoral artery (SFA) disease.

  • Categories:Academic Paper
  • Author:
  • Origin:
  • Time of issue:2016-08-12 09:22
  • Views:
Information

  OBJECTIVES: This study sought to evaluate the safety and performance of the Igaki-Tamai (Igaki Medical Planning Company, Kyoto, Janpan) biodegradable stent in patients with occlusive superficial femoral artery (SFA) disease.

  BACKGROUND: Poly-L-lactic acid (PLLA) biodegradable stents have been shown to be effective in the coronaries, but no data are available regarding their efficacy in the femoral artery.

  METHODS: A prospective, multicenter, nonrandomized study enrolled 30 patients with symptomatic de-nonv SFA diease undergoing implantation of Igaki-Tamai bioresorbable stents. Clinical examinations and duplex ultrasound were prospectively performed after 1, 6, 9, and 12 months. The main study endpoints were technical success, restenosis rate, rate of target lesion revascularization (TLR), changes in ankle-brachial index (ABI), and quality of life by evaluating the walking impairment questionnaire (WIQ). Safety was assessed by monitoring the occurrence of major adverse clinical events and serious adverse events.

  RESULTS: The mean age of the patients was 67.7 years, and 77% were male. The mean lesion length was 5.9 cm. Mean diameter stenosis was reduced from 89.9% to 6.2%, after stent implantation. Technical success was 96.7%. Binary restenosis rate for the 6 and 12 months follow-up was 39.3% and 67.9%, respectively. The TLR rate was 25.0% after 6 months and 57.1% after 12 months. All TLR were successful; the secondary patency rate after 1 year was 89.3%. Between baseline and 12 months, ABI increased in 53.6% of patients. Functional endpoints (WIQ), even if affected by a relatively high reintervention rate, showed improvement in most of the patients.

  CONCLUSIONS: The GAIA ( Evaluation of the Biodegradable Peripheral Igaki-Tamai Stent in the Treatment of De Novo Lesions in the SuperficialFemoral Artery) study shows that when using biodegradable PLLA stents (Igaki-Tamai), the immediate angiographic results are comparable to the results of metal stents, achieving a high secondary patency rate after 1 year. Modifications of stent characteristics and technical modifications are needed with the goal to reduce the restenosis rate during the reabsorption period.

PeriSorb® fully degradable peripheral vascular stent completes the first FIM trial enrollment
2021 12-25

PeriSorb® fully degradable peripheral vascular stent completes the first FIM trial enrollment

This is the world's first 3D printed fully degradable peripheral stent implanted in the human body, marking that my country's 3D printing fully degradable peripheral stent with completely independent intellectual property rights has taken the lead in entering the clinical trial stage, and it also marks that my country's 3D printing technology has advanced to the world's leading level. A big step.
Beijing adds 1,150 municipal-level "specialized, special and new" small and medium-sized enterprises
2021 12-03

Beijing adds 1,150 municipal-level "specialized, special and new" small and medium-sized enterprises

On December 1, the Beijing Economic and Information Bureau announced the list of the second to seventh batch of "specialized, special and new" small and medium-sized enterprises in Beijing in 2021. The list includes 1,150 small and medium-sized enterprises including Labtech, Digital Video, Geling Shentong, Moji Fengyun Technology, etc.
Beijing Amet was recognized as a "specialized, special and new" enterprise
2021 12-02

Beijing Amet was recognized as a "specialized, special and new" enterprise

On December 1, 2021, the Beijing Municipal Bureau of Economy and Information issued an announcement on the seventh batch of "specialized, refined, and new" small and medium-sized enterprises in 2021. The announcement announced that Beijing Amet Medical Equipment Co., Ltd. was recognized as a "specialized, refined and new" enterprise. This event marks that Amet, as an innovative enterprise, has reached a high level in terms of scientific research strength, technical level and influence, and has been recognized by the competent government departments.

Company Information

Beijing Advanced Medical Technologies,Ltd.Inc.

Contact Us

Address: Building 11, Zhongguancun Medical Equipment Park, No. 26, Yongwang West Road, Daxing District, Beijing

Tel:010-6297-7955           E-Mail:amt@ametcorp.com